4D Molecular Therapeutics/FDMT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.

Ticker

FDMT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

David Kirn

Employees

171

Headquarters

Emeryville, United States

FDMT Metrics

BasicAdvanced
$1.2B
Market cap
-
P/E ratio
-$2.36
EPS
2.88
Beta
-
Dividend rate
$1.2B
2.87601
$36.25
$9.44
601K
32.652
-23.93%
-25.53%
-24.71%
60.594
2.042
2.064
826.73%
30.26%
15.04%

What the Analysts think about FDMT

Analyst Ratings

Majority rating from 10 analysts.
Buy

FDMT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100.00%
Net income
-$32M
-67.86%
Profit margin
0.00%
-100.00%

FDMT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 10.41%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.77
-$0.24
-$0.75
-$0.66
-
Expected
-$0.81
-$0.59
-$0.74
-$0.74
-$0.71
Surprise
-4.70%
-59.58%
1.18%
-10.41%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for 4D Molecular Therapeutics stock?

4D Molecular Therapeutics (FDMT) has a market cap of $1.2B as of June 20, 2024.

What is the P/E ratio for 4D Molecular Therapeutics stock?

The price to earnings (P/E) ratio for 4D Molecular Therapeutics (FDMT) stock is 0 as of June 20, 2024.

Does 4D Molecular Therapeutics stock pay dividends?

No, 4D Molecular Therapeutics (FDMT) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next 4D Molecular Therapeutics dividend payment date?

4D Molecular Therapeutics (FDMT) stock does not pay dividends to its shareholders.

What is the beta indicator for 4D Molecular Therapeutics?

4D Molecular Therapeutics (FDMT) has a beta rating of 2.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the 4D Molecular Therapeutics stock price target?

The target price for 4D Molecular Therapeutics (FDMT) stock is $52.3, which is NaN% below the current price of $. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell 4D Molecular Therapeutics stock

Buy or sell 4D Molecular Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing